Benutzer: Gast  Login
Titel:

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype

Dokumenttyp:
Zeitschriftenaufsatz
Autor(en):
Orben, Felix; Lankes, Katharina; Schneeweis, Christian; Hassan, Zonera; Jakubowsky, Hannah; Krauß, Lukas; Boniolo, Fabio; Schneider, Carolin; Schäfer, Arlett; Murr, Janine; Schlag, Christoph; Kong, Bo; Öllinger, Rupert; Wang, Chengdong; Beyer, Georg; Mahajan, Ujjwal M.; Xue, Yonggan; Mayerle, Julia; Schmid, Roland M.; Kuster, Bernhard; Rad, Roland; Braun, Christian J.; Wirth, Matthias; Reichert, Maximilian; Saur, Dieter; Schneider, Günter
Abstract:
Systemic therapies for pancreatic ductal adenocarcinoma (PDAC) remain unsatisfactory. Clinical prognosis is particularly poor for tumor subtypes with activating aberrations in the MYC pathway, creating an urgent need for novel therapeutic targets. To unbiasedly find MYC-associated epigenetic dependencies, we conducted a drug screen in pancreatic cancer cell lines. Here, we found that protein arginine N-methyltransferase 5 (PRMT5) inhibitors triggered an MYC-associated dependency. In human and mu...     »
Stichworte:
BayBioMS; Cancer; Cell Biology; Oncology; Pharmacology
Zeitschriftentitel:
JCI Insight
Jahr:
2022
Band / Volume:
7
Heft / Issue:
10
Volltext / DOI:
doi:10.1172/jci.insight.151353
Verlag / Institution:
American Society for Clinical Investigation
E-ISSN:
2379-3708
Publikationsdatum:
23.05.2022
 BibTeX